References

Real-world effectiveness of cenobamate in drug-resistant and ultra-refractory epilepsy: a multicenter study

10.1002/epi4.70298 · 2026 · External reference

Neuropsychological and behavioral effects of antiepilepsy drugs

10.1007/s11065-007-9043-9 · 2007 · External reference

Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters

10.1016/j.euroneuro.2015.07.027 · 2015 · External reference

The cognitive impact of antiepileptic drugs

10.1177/1756285611417920 · 2011 · External reference

Which drug-induced side effects would be tolerated in the prospect of seizure control?

10.1016/j.yebeh.2013.07.013 · 2013 · External reference

Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: a retrospective study using Bayes statistics

10.1111/epi.16576 · 2020 · External reference

Cognitive effects of GABAergic antiepileptic drugs

2010 · External reference

How can we overcome neuropsychological adverse effects of antiepileptic drugs?

10.1080/14656566.2017.1309025 · 2017 · External reference

Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms

2022 · External reference

Positive allosteric modulation of GABAAreceptors by a novel antiepileptic drug cenobamate

2020 · External reference

Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability

10.1007/s40263-021-00819-8 · 2021 · External reference

Mass balance, metabolism, and excretion of cenobamate, a new antiepileptic drug, after a single oral administration in healthy male subjects

10.1007/s13318-020-00615-7 · 2020 · External reference

Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?

2023 · External reference

Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies

10.1016/j.yebeh.2023.109605 · 2024 · External reference

Effects of cenobamate on cognitive performance of epilepsy patients

10.1016/j.seizure.2022.10.004 · 2022 · External reference

Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy

10.1002/epi4.12857 · 2024 · External reference

Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study

10.1007/s40263-024-01063-6 · 2024 · External reference

Severe memory decline along with unaffected executive functions under 400 mg/day of cenobamate leading to a collapse in school performance

10.1080/13554794.2024.2366472 · 2024 · External reference

The effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy

10.1007/s40263-025-01196-2 · 2025 · External reference

Unresolved reference

2006 · External reference

Unresolved reference

External reference

Unresolved reference

2008 · External reference

Unresolved reference

2001 · External reference

Unresolved reference

1992 · External reference

The hospital anxiety and depression scale

10.1111/j.1600-0447.1983.tb09716.x · 1983 · External reference

Validation of the hospital anxiety and depression scale in patients with epilepsy

10.1016/j.yebeh.2016.03.003 · 2016 · External reference

A comparison of methods for measuring cognitive change in older adults

10.1016/j.acn.2004.08.002 · 2005 · External reference

Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease

10.1097/hcr.0000000000000379 · 2019 · External reference

Cenobamate plasma levels in patients with epilepsy: correlation with efficacy and tolerability?

10.3390/jcm13102757 · 2024 · External reference

Psychiatric effects of cenobamate in adults with epilepsy: a retrospective study

10.1016/j.yebeh.2025.110838 · 2026 · External reference